Skip to main content
main-content

05-04-2018 | Uveal melanoma | Podcast | Audio

SUMIT: Selumetinib in metastatic uveal melanoma

Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma.

image credits